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The nocebo reaction, namely the undesirable effect of an inert substance (placebo), is a phe-
nomenon rarely investigated in literature. A better knowledge of this reaction may help cli-
nicians in the management of these patients in clinical practice. Patients with drug adverse 
reactions (ADR) undergoing the drug challenge test are an ideal model for studying the nocebo 
effect, and the study aims to investigate their clinical and psychological features. One hundred 
and twenty patients (M
age
 = 46.59, SD = 15.5; 82% female), of which 90 non responders 
and 30 with nocebo reactions (25%) were recruited, and completed a battery of psychologi-
cal measures: State-Trait Anxiety Inventory X1-X2, Beck Depression Inventory II, Symptoms 
Checklist-90-R, Difficulties in Emotion Regulation Scale, Toronto Alexithymia Scale. Clini-
cal features (individual characteristics and ADR clinical history) were collected by clinicians. 
The results show that older age (p = 0.002), low level of education (p = 0.039) and a depres-
sive tendency (p = 0.030) appear to be potential risk factors for nocebo effects. Although none 
of the features related to the previous clinical history appear to represent a risk factor for the 
nocebo reactions (p > 0.05), significant correlations between some of the clinical and psycho-
logical characteristics considered (p values from 0.005 to 0.042) help to better delineate the 
profile of these reactive patients. A specific training of the sanitary team about psychological 
aspects is recommendable.
Patients with adverse drug reactions (ADR) are an ideal model 
for studying the nocebo effect, because their previous experience 
can generate a negative expectation conditioning their accep-
tance and results of subsequent therapies. In many ADR cases, 
the allergy diagnostic workup includes the systemic challenge 
(oral or parenteral), to confirm the responsibility of a drug in 
the reaction and to identify alternative drugs that can be safely 
used (6). The experience of allergists is that some patients may 
show negative reactions to the administration of an inert sub-
stance (placebo) which usually precedes the active drug. The 
practice using placebo has the purpose to better evaluate the test 
results, evidencing a possible adverse reaction - the nocebo effect 
- that is reported by literature in percentages ranging from 3% 
to 27% (7,8,9). Lombardi and colleagues (8) stressed that the 
Introduction
The term “nocebo” was originally used to differentiate the un-
desirable effects following the administration of an inert sub-
stance that the patient believes to be an active drug (during 
both pharmacological treatment and challenge test experimen-
tal studies). It is defined as the negative equivalent of the known 
placebo phenomenon. The nocebo reaction usually occurs in 
a subjective way with nonspecific symptoms (gastrointestinal 
symptoms, dizziness, headache, itching, paresthetic and ther-
mal sensations), but sometimes also with objective signs (cu-
taneous, respiratory, gastric, cardiac rhythm or blood pressure 
changes). Like the placebo effect, the nocebo effect can have an 
important impact on the clinical practice and the outcome of 
clinical trials (1,2,3,4,5).
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quality of medical-patient communication, and the empathetic 
approach by medical and nursing staff could be associated with 
a lower frequency of nocebo reactions.
Therefore, it is important to improve the clinical practice check-
ing whether there are variables regarding the type of reactions 
experienced by patients, or particular psychological features 
enabling specialists to identify such subjects before submitting 
them to challenge tests (10). This may require specific training 
of specialists, but could be useful to increase the reliability of the 
allergy diagnostic workup.
The present study aims to investigate the clinical (individual 
characteristics and ADR clinical history) and psychological fea-
tures (anxiety, depression, psychological symptoms, emotion 
dysregulation, and alexithymia) of patients with nocebo effect 
to oral challenge test compared with patients without reactions. 
At the exploratory level, the association between clinical and 
psychological features in nocebo patients are also investigated, 
to better delineate the profile of the reactive patients.
Materials and methods 
Among all the patients with a clinical history of ADR, 120 were 
recruited consecutively from the Allergy Unit of the San Mar-
tino IST University Hospital (Genoa, Italy) in the first months 
of 2016, because they needed to be submitted to challenge test. 
The allergist proposed and asked the patient consent to take 
part in the study. This study was conducted following the ethi-
cal standards established in the Declaration of Helsinki of 1946. 
Based on the clinical features of the ADR, the allergist decided 
the diagnostic workup in agreement with the patient, including 
the oral challenge test for one or more drugs. In the first day, af-
ter clinical evaluation of the patient including heart rate, blood 
pressure, and respiratory function, four doses of a placebo (wa-
ter or talc) were administered at 30’ intervals in a single-blind 
way. The patient was observed for one hour after the last dose 
and re-evaluated by the sanitary team before leaving the hospi-
tal. The day after, before the active drug administration, patients 
were required to report any symptoms at home. At the begin-
ning of the test, a battery of psychological questionnaires was 
proposed by the psychologists to the patient, with the task of 
completing them by the first day.
Two groups of patients, negative (n = 90) and positive (n = 30) 
for nocebo effects occurring after administration of the “placebo” 
were selected and compared in this study. Socio-demographic 
features, associated pathologies and clinical characteristics of the 
ADR were analyzed (i.e. number of reactions, number and class 
of drugs involved, timing and severity of symptoms, emergency 
services access, history compatible with drug hypersensitivity 
diagnosis). The battery of psychological self-report adminis-
tered (validated in Italian context) are summarized in table I.
Table I - Battery of psychological questionnaire for psychological assessment. 
Measure Questionnaire (authors) Number of items Subscales









(SCL-90-R, 14) 90 
somatization (SOM)
obsessive-compulsive (O-C) 











difficulties in emotion 
regulation scale (DERS, 15) 36
non-acceptance of emotional response (Non-acceptance)
difficulties engaging in goal-directed behavior (Goal)
impulse control difficulties (Impulse)
lack of emotional awareness (Awareness)
limited access to emotion regulation strategies (Strategies)
lack of emotional clarity (Clarity)
total score (DERS Total)
alexithymia Toronto alexithymia scale (TAS-20, 16) 20
difficulty in identifying feelings (DIF)
difficulty in describing feelings (DDF)
external oriented thinking (POE)
total score (TAS-20 Total)
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Clinical data collected by the clinicians in a data sheet were ana-
lyzed in aggregated form using the Statistical Package for Social 
Science (Version 23.0; IBM Corp., Armonk, NY, USA). Chi 
square test and independent-sample t test were used to com-
pare the clinical and psychological features of two groups. The 
multivariate analysis was used to control the effect of socio-de-
mographic data differing two groups. Point biserial correlations 
were used to compare the association between nominal (clinical 
data) and quantitative variables (psychological measures). The 
level of significance for all analyses was p < 0.05. 
Results
One hundred and twenty patients (M
age
 = 46.59, SD = 15.5; 
82% female) evaluated for an ADR clinical history completed the 
allergy and psychological tests. A nocebo effect was observed in 
thirty patients (25%), of which 18 complained symptoms during 
or within one hour after the last dose of placebo administration 
and 12 reported reactions later, at home. Most of the symptoms 
were subjective, with a few cases of objective reactions: 27% 
skin symptoms (itching, burning sensation, paresthesia), 
33% neurological symptoms (agitation, tremors, dizziness, 
headache), 20% gastrointestinal symptoms (nausea, abdominal 
pain, diarrhea), 10% respiratory symptoms (dyspnea, laryngeal 
obstruction sensation), 10% cardiovascular symptoms (hypo or 
hypertension, tachycardia). Some patients complained more than 
one symptom, in four cases both in hospital than later, at home. In 
almost all cases the reactions were mild and patients immediately 
evaluated by the responsible allergist. Only one patient refused to 
continue the test, the day after, with active drug.
Comparing patients with nocebo reactions (n = 30) with non 
responders (n = 90) respect to some socio-demographic data 
and associated pathologies (table II), significant differences on 
age (nocebo group: M
age
 = 54.20, SD = 12.77; non  responders 
group: M
age
 = 44.06, SD = 15.56; t
(118)
 = 3.22, p = 0.002) and 
educational level (nocebo group: 33% had the junior high 
school license; non responders group: 16% had the junior high 
school license; X2
(2)
 = 6.47, p = 0.039) were found. The two 
groups differed only marginally for gender (nocebo group: 93% 
female; non responders group: 78% female; X2
(1)
 = 3.64, p = 
0.057). No significant difference resulted for associated pathol-
ogies, including atopy. 
Table III shows the clinical features (i.e. number of drug reac-
tions, number of implicated drugs, timing of reactions, symp-
toms, severity of reactions, emergency services access, and com-
patible diagnosis of drug hypersensitivity) comparing patients 
with nocebo reactions with non responders. No significant dif-
ference was found (p > 0.05). 
In table IV are shown the results of psychological assessment (i.e. 
anxiety, depression, psychological symptoms, emotional regula-
tion-dysregulation, and alexithymia), comparing patients with 
nocebo reactions with non responders. The only significant dif-
ference (even if minimal) between the two groups was found on 
SCL-90-R Depression (t
(118)
 = 2.19, p = 0.030), showing higher 
level of depression symptoms in nocebo patients (M = 2.00, SD 
= 0.88) than in non responders (M = 1.69, SD = 0.58).
Table II - Socio-demographic data and associated pathologies of patients. 
Patients with nocebo 




Gender (%) female 93 78 X2
(1)
 = 3.64, p = 0.0572
male 7 22
Mean age (SD) 54.20 (12.77) 44.06 (15.56) t
(118)
 = 3.22, p = 0.0021
Educational level (%)




 = 6.47, p = 0.0391
high school diploma 40 65
degree 27 19
Association with other 
pathology (%)




yes 30 30 X2(1)
 = 0.00, p = 1.000
no 70 70
p < 0.051; p< 0.102
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Table III - Clinical features of ADR patients: the comparison between patients with nocebo effects and non responders.
Patients with nocebo 




Number of drug reactions (%) 1 20 25.6 X2
(1)
 = 0.38, p = 
0.538
> 1 80 74.4
Number of implicated drugs (%) 1 43.3 55.6 X2
(1)
 = 1.35, p = 
0.246
> 1 56.7 44.4
Timing of reactions (%) immediate 63.3 46.7 X2
(2)
 = 5.30, p = 
0.071
not immediate 13.3 35.6
both 23.3 17.8
Symptoms (%) mono-symptomatic 80 62.9 X2
(1)
 = 2.97, p = 
0.085
multi-symptomatic 20 37.1
Severity of reactions (%) mild 37.9 29.9 X2
(2)




Emergency services access (%) yes 50 51.7 X2
(1)
 = 0.02, p = 
0.873
no 50 48.3
Compatible drug hypersensitivity 
diagnosis (%)
probable 86.2 85.4 X2
(1)
 = 0.01, p = 
0.914
not probable 13.8 14.6
Table IV - Values and differences in psychological data resulting from the specific questionnaires.
Patients with nocebo 
reactions M (SD)
Non responders M (SD) Statistics t (118)
CBA State Anxiety 46.21 (33.27) 40.83 (28.58) 0.86
Trait Anxiety 37.52 (28.36) 37.55 (26.60) -0.01
Beck-II Depression 11.60 (10.30) 7.96 (7.83) 2.03
SCL-90-R SOM 1.96 (0.67) 1.67 (0.55) 2.34
O-C 1.83 (0.67) 1.70 (0.53) 1.05
I-S 1.68 (0.69) 1.54 (0.54) 1.14
DEP 2.00 (0.88) 1.69 (0.58) 2.191
ANX 1.78 (0.73) 1.57 (0.53) 1.68
HOS 1.67 (0.65) 1.48 (0.50) 1.72
PHOB 1.32 (0.68) 1.25 (0.42) 0.68
PAR 1.88 (0.71) 1.68 (0.58) 1.56
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Patients with nocebo 
reactions M (SD)
Non responders M (SD) Statistics t (118)
PSY 1.40 (0.54) 1.29 (0.33) 1.31
GSI 1.77 (0.60) 1.58 (0.42) 1.91
DERS Non-Acceptance 12.27 (5.13) 12.49 (4.99) -0.21
Goals 13.10 (3.27) 13.29 (3.60) -0.25
Impulse 11.43 (2.86) 11.61 (3.14) -0.27
Awareness 23.43 (4.41) 22.67 (3.55) 0.96
Strategy 16.87 (5.22) 15.81 (4.01) 1.15
Clarity 12.80 (1.19) 13.20 (1.36) -0.14
Total 89.90 (15.29) 89.07 (13.03) 0.29
TAS-20 DIF 13.00 (5.46) 13.29 (5.23) -0.26
DEF 13.00 (4.50) 12.42 (3.25) 0.76
POE 27.07 (3.61) 26.82 (3.73) 0.31
Total 106.60 (14.43) 104.32 (14.98) 0.73
1p < 0.05
Table IV (continued)
Table V - Point biserial correlations between clinical and psycho-
logical data in nocebo patients. 




CBA Trait Anxiety - -0.4371











TAS-20 Total  - -0.4471
1p < 0.05; 2p < 0.01
To control age and educational level differences on psycholog-
ical subscales scores between patients with nocebo group and 
non responders, multivariate analysis was applied. Findings 
showed no significant effect for educational level and for group 
F < 1, but significant effect for age, F (1, 119) = 1.88, p = 0.018, 
eta2 = 0.32. Significant interaction between educational level 
and group was found, F (1, 119) = 0.51, p = 0.025, eta2 = 0.28.
At the exploratory level, the association between clinical and 
psychological features on nocebo group was analyzed. Signifi-
cant correlations are shown in table V. Emergency services ac-
cess (0 = access, 1 = non access) are negatively correlated with 
trait anxiety of CBA (r
b 
= -0.437, p = 0.016), and with TAS to-
tal (r
b
 = -0.447, p = 0.013). The time of previous drug reactions 
(0 = immediate;  1= non immediate reactions ) is positively cor-
related with various subscales of DERS (Non-acceptance, Im-
pulse, Strategy, DERS Total) and SCL-90-R subscales (SOM, 
O-C, DEP, HOS, GSI) with p values from 0.042 to 0.005.
Discussion 
This is one of the few studies focused on patients with nocebo 
reactions to the placebo administration during the pharmaco-
logical challenge. The result as frequency of patients with noce-
bo reactions (25%) is in line with other studies (7,9), and higher 
than that of 3% reported and attributed by Lombardi (8) to the 
absence of cases of severe reactions in his sample of patients.
As in other studies, the nocebo symptoms were subjective and of 
mild severity in almost all cases, such as not able to hinder the 
continuation of the test after clinical examination, but perceived 
as troublesome by patients. Notably, more than one-third of re-
sponders experienced reactions after several hours at home, de-
spite a history of previous immediate drug reactions. The remain-
der complained about immediate symptoms or within one hour 
from the last dose of placebo administered in the hospital. This 
is not comparable with other studies, but deserves attention be-
cause it could be a key factor for the responders and have relevant 
practical implications, as the need to instruct the patient about 
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their possible appearance and their management. In any case, in-
terpretation and discussion of the reactions with the patient may 
represent a problem for the clinicians and nurses involved.
The analysis of the socio-demographic data shows a prevalence 
of the female gender in line with the literature (7) in the nocebo 
group compared to non responders. Age and level of education 
are variables not previously reported as influential, while in our 
study higher age and lower level of education characterize the 
responders. 
Considering that patient’s expectation and previous experiences 
of untoward reactions to drugs are the main factors influencing 
the nocebo effect (2,3), some of the clinical features of the previ-
ous drug reactions can be assumed as risk-factors. In our study, 
although 80% of responders reported more than one ADR, pre-
dominantly immediate (over 60%), with compatible symptoms 
of hypersensitivity to drugs, and of moderate-severe degree (in 
62% of cases), no significant difference has been demonstrated 
between the two groups. 
According to the aim of this work to outline the profile of re-
sponders, various psychological variables were also analyzed (i.e. 
anxiety, depression, psychological symptoms, emotional regula-
tion-dysregulation, and alexithymia). The only factors associat-
ed in the literature to the nocebo phenomenon are somatization 
tendency, anxiety and depression (8,11), the latter suggested as 
a general feature of the ADR population (10). In our study, the 
only datum that seems to delineate the psychological profile of 
responders (controlling the effects of age and educational level) 
is the presence of depressive symptoms that confirm the data 
of the literature, while anxiety and somatization tendency, are 
not confirmed. These findings could reinforce the key-role that 
other factors, as negative expectation and pavlovian condition-
ing process with the consequent involvement of neurobiological 
mediators, play in nocebo reactions, as evidenced by studies of 
Benedetti (17) and Colloca (3). A more detailed analysis of the 
individual variables, however, shows that higher levels of trait 
anxiety and alexithymia appears to be associated with more fre-
quent access to emergency services. In other words, this datum 
suggests that anxiety and alexithymia are individual features 
making the nocebo patients more vulnerable to call for help. 
Besides, psychological symptoms and emotional dysregulation 
appear to be associated with the late-onset drug reactions. This 
could be interpreted with the greater vulnerability of nocebo 
patients to psychological discomfort, and with the greater dif-
ficulty of these patients to acceptance, evaluation and dealing 
with the drug reactions. 
Conclusions 
Despite the limitations of the study, such as the low sample size 
and the use of self-report measures, the findings seem to be clin-
ically relevant. Female sex, older age and low level of education 
combined with a depressive tendency appear to be potential risk 
factors for nocebo effects appearing during oral challenge test in 
one among four patients. However, none of the features related 
to the previous clinical history of ADR appear to be associated 
with the possibility of nocebo reactions. Although various psy-
chological features do not seem to outline a typical profile of 
responders, some of these patients show psychological symptoms 
and emotional problems significantly associated with the time of 
previous drug reactions and with the use of emergency services. 
In view of this, the training of the sanitary team dedicated to 
pharmacological challenges must include the psychological as-
pects (18). The verbal communication between health caregiv-
ers and patient, the patient education with respect to possible 
reactions, the understanding of what the patient needs to know 
about adverse effects, and the general clinical context are key 
factors for a proper assessment of this diagnosis, burdened with 
time and human resources high costs (5,11).
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